Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)

• Status: Withdrawn
• Trial end date: 2016-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the safety of Xarelto in the prophylaxis of VTE in Indian patients undergoing elective TKR/THR

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• Adult patients of either sex, undergoing elective THR/TKR, in whom, Rivaroxaban is given for thromboprophylaxis

• Patients willing to give a written informed consent

Exclusion Criteria:

• Exclusion criteria must be read in conjunction with the local product information

• Patients on UFH / LMWH therapy, fondaparinux and vitamin K antagonists are not eligible.

• Patients with history of hypersensitivity to active ingredients or excipient :cellulose microcrystalline, croscarmellose sodium, lactose monohydrate, magnesium stearate, sodium lauryl sulfate